The Immune Directed Individualized Elimination Therapy (iDIET) Study (iDIET)
An Allergen-specific Immune Signature-directed Diet vs Sham Diet for Treatment of Eosinophilic Esophagitis: A Pilot-feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomized in a 1:1 fashion to follow an allergen-specific immune signature-directed diet or sham diet during the 8-week treatment period. Blood and biopsies specific to this study will be collected during a baseline endoscopy completed as part of their routine clinical care. Samples will be immediately transported to a lab in which T-cell and immunoglobulin G4 (IgG4) signatures will be analyzed for the full 18 food panel. If randomized to the active intervention, then participants in a blinded fashion will be assigned a diet that removes the foods for which they had a positive threshold result on either the T-cell or IgG4 assay. If randomized to the sham diet, then participants will be provided a sham diet. Sham diets will be developed via selecting a random number of foods from a random list of the potential eliminated foods. The participant, investigators, clinical research coordinators, and study dietician will be blinded to the results of laboratory analysis during the course of the study. The lab, study monitor, or other designee not otherwise involved in the study will be unblinded.
Upon assignment of their diet intervention, participants will meet with a study dietician to discuss their baseline food consumption and assigned diet intervention. After 4 and 8 weeks of diet intervention, they will check-in with the study dietician. In addition, they will monitor their food intake for compliance. At the end of the 8-week treatment period, participants will return for an endoscopy with biopsies and blood draw. Upon completion of the 8-week endoscopy, participation in this study is complete and participants will return to routine care of their condition which may include dietary re-introduction if clinically indicated after completion of the iDIET study.
The primary hypothesis is that participants treated with the immune-signature diet will have significantly lower post-treatment eosinophil counts and dysphagia symptom scores than participants treated with sham diet.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- The University of North Carolina At Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Age: 16 - 80 years
- Diagnosis of EoE as per consensus guidelines
- No prior treatment with, or documented failure of, dietary elimination therapy. Failure is defined as =>15 eos/hpf after a course of the six-food elimination diet (SFED).
- On stable diet for 4 weeks prior to screening endoscopy and agree to maintain throughout course of participation. Foods eliminated for allergic or other reactions are not exclusionary and may continue to be avoided throughout participation in the study regardless of food trigger results.
In addition to meeting the above criteria, to be eligible for randomization an individual must meet all of the following criteria:
- Active EoE (=>15 eos/hpf) based on clinical biopsies taken during baseline endoscopy
- Must have at least one positive food on the IgG4 or T cell stimulation assay
Exclusion Criteria:
- Concomitant eosinophilic gastritis and/or enteritis, confirmed with a prior clinicohistologic diagnosis
- Use of systemic corticosteroids within 4 weeks of the baseline/qualifying endoscopic exam
- Previous esophageal resection
- History of bleeding disorder or esophageal varices
- Current use of blood thinners such as coumadin, warfarin, heparin, and/or novel anticoagulant agents (requires discontinuation of medication within an appropriate time frame for that specific agent and in accordance with standard clinical practice)
- Medical instability that precludes safely performing upper endoscopy
- Inability to read or understand English
- Pregnancy or breastfeeding
- Body mass index (BMI) <17
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Individualized Diet Elimination Therapy
Subjects in this arm will be assigned an allergen-specific immune signature-directed diet to follow for 8 weeks
|
An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm.
Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
|
|
Placebo Comparator: Sham Diet Elimination Therapy
Subjects in this arm will be assigned a sham diet to follow for 8 weeks
|
Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-treatment Peak Eosinophil Count
Time Frame: 8 weeks
|
Post-treatment peak eosinophil count (measured in eos/hpf)
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Histologic Responders
Time Frame: 8 weeks
|
Histologic response is defined as an esophageal eosinophil count of <15 eos/hpf, a threshold previously determined to be optimal for response assessments in EoE studies
|
8 weeks
|
|
Dysphagia Symptom Score
Time Frame: 8 weeks
|
Dysphagia symptom score, as measured by the validated Eosinophilic Esophagitis Activity Index (EEsAI) instrument This score ranges from 0-100, with higher scores indicating more severe symptoms.
A score of < 20 indicates clinical remission.
|
8 weeks
|
|
Endoscopic Severity
Time Frame: 8 weeks
|
Endoscopic severity will be assessed using the validated EoE Endoscopic Reference Score (EREFS).
This score measures endoscopic severity with a set of five endoscopic findings (exudates, rings, edema, furrows, and strictures), and ranges from 0-9, with higher scores indicating higher endoscopic severity.
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Evan S Dellon, MD, MPH, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-0500
- R01DK132001 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.